Conflixis, a pioneering provider of conflict of interest risk management technology, has unveiled its inaugural 2024 Open Payments Report. This comprehensive analysis sheds light on the intricate financial relationships between healthcare providers and the pharmaceutical and medical device industries.
“The insights from our technology underscore the vital role of transparency and data analysis in helping healthcare employers navigate conflicts of interest,” remarked Conflixis CEO Aaron Narva.
Key findings from the report reveal patterns indicating potential inappropriate remuneration. Despite increased transparency through programs like Open Payments, certain payment practices have become more prevalent rather than diminishing. These include complex combinations of consulting fees, speaking engagements, promotional fees, and in-kind payments for hospitality.
Narva emphasized, “Our report aims to highlight broader trends in financial interactions within the healthcare sector, urging stakeholders to take proactive measures.”
Established in 2013 by the Centers for Medicare and Medicaid Services (CMS), the Open Payments program aims to enhance transparency by documenting payments made to healthcare providers by pharmaceutical and medical device companies. This includes fees for consulting, speaking engagements, honoraria, and various in-kind payments.
About Conflixis:
Conflixis specializes in mitigating conflicts of interest through advanced risk management solutions. Leveraging extensive experience in anti-corruption and fraud prevention, Conflixis offers a sophisticated platform for real-time analysis of internal and public data sets, enabling organizations to effectively manage conflict-related risks.
